Ameriprise’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $793K | Buy |
85,990
+1,233
| +1% | +$11.4K | ﹤0.01% | 3333 |
|
2025
Q1 | $727K | Buy |
84,757
+17,947
| +27% | +$154K | ﹤0.01% | 3316 |
|
2024
Q4 | $718K | Buy |
66,810
+3,243
| +5% | +$34.8K | ﹤0.01% | 3360 |
|
2024
Q3 | $361K | Buy |
63,567
+85
| +0.1% | +$483 | ﹤0.01% | 3581 |
|
2024
Q2 | $268K | Sell |
63,482
-730
| -1% | -$3.08K | ﹤0.01% | 3619 |
|
2024
Q1 | $327K | Buy |
64,212
+9,560
| +17% | +$48.7K | ﹤0.01% | 3559 |
|
2023
Q4 | $509K | Buy |
54,652
+18,277
| +50% | +$170K | ﹤0.01% | 3444 |
|
2023
Q3 | $238K | Buy |
36,375
+2,914
| +9% | +$19.1K | ﹤0.01% | 3648 |
|
2023
Q2 | $272K | Sell |
33,461
-15
| -0% | -$122 | ﹤0.01% | 3635 |
|
2023
Q1 | $287K | Sell |
33,476
-174
| -0.5% | -$1.49K | ﹤0.01% | 3625 |
|
2022
Q4 | $312K | Buy |
33,650
+13,895
| +70% | +$129K | ﹤0.01% | 3572 |
|
2022
Q3 | $203K | Buy |
19,755
+2,350
| +14% | +$24.1K | ﹤0.01% | 3698 |
|
2022
Q2 | $174K | Buy |
17,405
+300
| +2% | +$3K | ﹤0.01% | 3703 |
|
2022
Q1 | $211K | Sell |
17,105
-5,860
| -26% | -$72.3K | ﹤0.01% | 3743 |
|
2021
Q4 | $398K | Sell |
22,965
-13,000
| -36% | -$225K | ﹤0.01% | 3587 |
|
2021
Q3 | $645K | Sell |
35,965
-26,195
| -42% | -$470K | ﹤0.01% | 3315 |
|
2021
Q2 | $1.42M | Sell |
62,160
-30,965
| -33% | -$708K | ﹤0.01% | 3062 |
|
2021
Q1 | $1.39M | Buy |
93,125
+24,725
| +36% | +$370K | ﹤0.01% | 2995 |
|
2020
Q4 | $369K | Buy |
68,400
+35,645
| +109% | +$192K | ﹤0.01% | 3430 |
|
2020
Q3 | $149K | Buy |
32,755
+17,685
| +117% | +$80.4K | ﹤0.01% | 3593 |
|
2020
Q2 | $74K | Sell |
15,070
-1,735
| -10% | -$8.52K | ﹤0.01% | 3601 |
|
2020
Q1 | $53K | Sell |
16,805
-4,200
| -20% | -$13.2K | ﹤0.01% | 3578 |
|
2019
Q4 | $54K | Buy |
21,005
+5,005
| +31% | +$12.9K | ﹤0.01% | 3665 |
|
2019
Q3 | $19K | Buy |
+16,000
| New | +$19K | ﹤0.01% | 3676 |
|